Investigating An Armored Allogeneic Anti-CD70 CAR γδ T Cell Therapy Designed for Enhanced Potency & Persistence Against Multiple Oncology Indications
Time: 11:00 am
day: Day Two
Details:
- Exploring a third generation armored allogeneic anti-CD70 CAR gamma delta T cell product
- Demonstrating rapid homing, activation and killing kinetics in preclinical models
- ADI-270 exhibited significant efficacy across multiple solid and hematological tumor models expressing various levels of CD70
